Lung targeting dual drug delivery system

US9421194B2 · kind B2 · utility

Assignees

• Rutgers, the State University of New Jersey · US
• THE TRUSTEES OF PRINCETON UNIVERSITY · US

Inventors

• Robert K. Prud'homme · Princeton, US
• Patrick J. Sinko · Lebanon, US
• Howard A. Stone · Princeton, US
• Nathalie M. Pinkerton · Princeton, US
• Lei Shi · Shanghai, CN
• Jiandi Wan · Lawrenceville, US
• Sherif Ibrahim · Old Bridge, US
• Dayuan Gao · East Brunswick Township, US

Key dates

• Filing date: Apr 5, 2011
• Grant date: Aug 23, 2016
• Expiry date: Apr 20, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The American Cancer Society estimated that in 2009, 1,479,350 new cancer cases would be diagnosed in the United States of which 219,440 would be lung and bronchus related. The standard treatments for NSCLC include surgery, chemotherapy, radiation, laser and photodynamic therapy, all with various success rates depending on the stage of the cancer. National Cancer Institute assesses, however, that results of standard treatment are generally poor with only a 15 percent 5-year survival rate for combined cancer stages. Challenges facing the current chemotherapy drugs include excessive toxicity to healthy tissues and limited ability to prevent metastases. A dual drug delivery system described herein selectively targets the lung to deliver anti-cancer drugs and inhibit the formation of metastases.